Nivolumab vs Rituximab

## Nivolumab vs Rituximab: Overview

This comparison examines the pharmacological differences between **Nivolumab** and **Rituximab**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

## Pharmacokinetics

**Half-life**: Nivolumab — 27 days; Rituximab — 22 days.

## Chemical Properties

**Type**: Nivolumab — Antibody; Rituximab — Antibody.